ADVAMED: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	5	1
2024	—	8	2
2023	—	8	2
2022	—	9	2
2021	—	7	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
MEHLMAN CONSULTING, INC.	—	16
EMERGENT STRATEGIES	—	24

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	38
SENATE	34
Environmental Protection Agency (EPA)	14
Executive Office of the President (EOP)	1
Office of Management & Budget (OMB)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	24
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	24
Computer Industry	Computer Industry	23
Trade (domestic/foreign)	Trade (domestic/foreign)	21
Environment/Superfund	Environment/Superfund	16
Medicare/Medicaid	Medicare/Medicaid	14

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · second_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

Show 21 more cited filings

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · second_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to S.1717 Ensuring Patient Access to Critical Breakthrough Products Act of 2025 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $15,000

Matched citations: S.1717

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2025 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to H.R.1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues on legislation pertaining to S.5349 Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $30,000

Matched citations: H.R.1691

S. 5349118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2025 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to H.R.1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues on legislation pertaining to S.5349 Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $30,000

Matched citations: S.5349

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2025 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to H.R.1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues on legislation pertaining to S.5349 Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R.1691

S. 5349118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2025 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues on legislation pertaining to H.R.1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues on legislation pertaining to S.5349 Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: S.5349

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2024 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349; Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

S. 5349118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2024 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349; Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: S.5349

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2024 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2024 · second_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2024 · first_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2023 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

H.R. 1691118th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

2023 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1691; Ensuring Patient Access to Critical Breakthrough Products Act of 2023 Issues related to transitional coverage of emerging technologies

Client expense: — · Firm income: $45,000

Matched citations: H.R. 1691

H.R. 4043117th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2021

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Health tax issues and trade, H.R.4043 - Ensuring Patient Access to Critical Breakthrough Products Act of 2021 Issues related to Small Business Innovation Research Program Medical Device User Fee Amendments IV

Client expense: — · Firm income: $30,000

Matched citations: H.R.4043

H.R. 4043117th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2021

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Health tax issues and trade, H.R.4043 - Ensuring Patient Access to Critical Breakthrough Products Act of 2021

Client expense: — · Firm income: $30,000

Matched citations: H.R.4043

H.R. 4521117th Congress

United States Innovation and Competition Act of 2021

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to semiconductor chips in S. 1260 - USICA and H.R.4521 - America COMPETES Act of 2022.

Client expense: — · Firm income: $30,000

Matched citations: H.R.4521

H.R. 8152117th Congress

American Data Privacy and Protection Act

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

issues related to data privacy. H.R. 8152 - American Data Privacy and Protection Act. S. 3195 - Consumer Online Privacy Rights Act

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8152

S. 1260117th Congress

United States Innovation and Competition Act of 2021

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to semiconductor chips in S. 1260 - USICA and H.R.4521 - America COMPETES Act of 2022.

Client expense: — · Firm income: $30,000

Matched citations: S. 1260

S. 3195117th Congress

Consumer Online Privacy Rights Act

2022 · third_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

issues related to data privacy. H.R. 8152 - American Data Privacy and Protection Act. S. 3195 - Consumer Online Privacy Rights Act

Client expense: — · Firm income: $30,000

Matched citations: S. 3195

H.R. 4043117th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2021

2022 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Health tax issues and trade, H.R.4043 - Ensuring Patient Access to Critical Breakthrough Products Act of 2021 Issues related to Small Business Innovation Research Program Medical Device User Fee Amendments IV

Client expense: — · Firm income: $30,000

Matched citations: H.R.4043

H.R. 4043117th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2021

2022 · fourth_quarter · Firm: EMERGENT STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Health tax issues and trade, H.R.4043 - Ensuring Patient Access to Critical Breakthrough Products Act of 2021

Client expense: — · Firm income: $30,000

Matched citations: H.R.4043

Source: Senate LDA

ADVAMED: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION — Lobbying Disclosure | Poliscope